drugset / Trial / NCT02733133

Product Transference Study of Testagen™ TDS®-Testosterone

NCT02733133

RandomizedParallel-groupOpen-labelPrevention

Summary

This study will assess the potential of Testagen® TDS-Testosterone to enable transfer of Testosterone to females coming in contact with skin to which Testagen® TDS-Testosterone has been applied and the potential of product to raise serum androgen levels in those women.

Timeline

Start
2027-01-05
Primary completion
2027-10
Completion
2027-12

Drugs

EvaluationDrugModalityDoseRoute
Subject Testosterone Small molecule 5 % Topical